J&S Preclinical Solutions

Finding solutions to your preclinical challenges
Our Expertise
Background

About us

Julien
Julien Villaudy
And
Sjeng Horbach

Senior Consultant Pharmacology

Julien Villaudy is an experienced pharmacologist with over 15 years of experience in academia and industry.

Principal Consultant Toxicology

Sjeng Horbach is a Toxicology expert with over 38 years of experience.

Our expertise

At J&S Preclinical Solutions, we are dedicated to propelling your preclinical drug development programs to new heights.

Our team of consultants is here to partner with you in designing, executing, and reporting comprehensive preclinical pharmacology and preclinical toxicology studies. We strongly believe that the integration of toxicology and pharmacology readouts early in the development program is an asset that will strengthen and accelerate your drug development.

Learn more about our expertise or come in contact to tell us more about your program.

Our clients

Lead Pharma
Lava therapeutics
Aimm therapeutics
AM-pharma
Eagle Rock
Merus
Halix
neuramedy
Trained Therapeutix Discovery
Amarna Therapeutics
Chondropeptix

Undisclosed Clients

For our drug discovery projects in preclinical development, we collaborate with Sjeng Horbach for conducting activities in preclinical toxicology and drug safety.
Next to expert contributions in this field, Sjeng plays an important role in the multidisciplinary project team dynamics, interpreting project data and aligning the various inter-disciplinary activities in one operational plan. His contributions have certainly enabled progression of our most advanced wholly-owned project through pre-clinical development.
Arthur Oubrie

CSO , Lead Pharma

Sjeng Horbach brings enormous experience in toxicology, building on an outstanding track record in supporting all stages of drug development for small and large molecules. I have had the pleasure of working with Sjeng on a large and diverse set of therapeutic antibodies ranging from canonical antibodies to antibody-drug conjugates and bispecific antibodies, with a recent emphasis on immune-oncology compounds including T-cell engagers. Sjeng is not only very knowledgeable and collaborative, but also very pleasant to work with. I recommend him most highly.

Paul Parren

EVP and Head of R&D, Lava Therapeutics

J&S Preclinial Solutions combines decades of preclinical safety assessment and cutting-edge in vivo efficacy experience in immunology/oncology with a getting-things done mentality and taking responsibility, accountability and on top of that great personalities. This mix is pushing any project at hand forward in a great Team spirit.

Hans van Eenenaam

CSO, AIMM Therapeutics